PhaseBio Reports First Quarter 2019 Financial Results and Recent Corporate Progress
May 09, 2019 16:01 ET
|
PhaseBio Pharmaceuticals, Inc.
Completed underwritten public offering of common stock that raised $46.2 million in net proceeds Received FDA Breakthrough Therapy designation for PB2452 Results from Phase 1 clinical trial of...
PhaseBio To Report First Quarter 2019 Financial Results and Recent Corporate Progress on May 9, 2019
May 02, 2019 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, May 02, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 16, 2019 16:01 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, April 16, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Announces Pricing of Public Offering of Common Stock
April 11, 2019 21:19 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., and SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Announces Proposed Public Offering of Common Stock
April 09, 2019 16:45 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, April 09, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Announces Global License of PB1023 for the Treatment of Sarcopenia-Related Diseases to ImmunoForge
April 09, 2019 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, April 09, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Receives FDA Breakthrough Therapy Designation for PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor
April 08, 2019 16:01 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, April 08, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Reports Fourth Quarter and Full-Year 2018 Financial and Business Results
March 26, 2019 16:01 ET
|
PhaseBio Pharmaceuticals, Inc.
Results from Phase 1 clinical trial of PB2452 published in the New England Journal of Medicine and presented at the American College of Cardiology’s Annual Scientific Session Initiated Phase 2b trial...
PhaseBio Announces Term Loan of up to $15 Million
March 25, 2019 16:30 ET
|
PhaseBio Pharmaceuticals, Inc.
Entered into term loan facility with Silicon Valley Bank and WestRiver Innovation Lending Fund to borrow up to $15 million Funds will be used to advance clinical development of PB2452, a reversal...
PhaseBio To Report Fourth Quarter and Full-Year 2018 Financial and Business Results on March 26, 2019
March 19, 2019 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, March 19, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...